Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer

Prostate

Volumn 69, Issue 10, 2009, Pages 1128-1141

  Liu, Chunsheng ^a   Hasegawa, Kosei ^a,c   Russell, Stephen J ^a   Sadelain, Michel ^b   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Oncolytic measles virus; Prostate cancer; PSMA targeting; Radiation

Indexed keywords

CD38 ANTIGEN; MEASLES VACCINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; CANCER VACCINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TUMOR REGRESSION; TUMOR XENOGRAFT; VIROTHERAPY; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; CERCOPITHECUS; COMPARATIVE STUDY; DRUG SCREENING; GENE TARGETING; GENETICS; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; METHODOLOGY; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE; VERO CELL; VIROLOGY;

ANIMALS; ANTIGENS, SURFACE; CANCER VACCINES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; GENE TARGETING; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; JURKAT CELLS; MALE; MEASLES VIRUS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449152194     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20962     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
2. Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: The Mayo Clinic experience. Urol Oncol 2008; 26(5):530-532.
3. Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005;65(6 Suppl):8-12. (Pubitemid 40804366)
4. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98(7):2002-2007.
5. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62(16):4656-4662. (Pubitemid 34898592)
6. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63(10):2462-2469. (Pubitemid 36605184)
7. Blechacz B, Splinter PL, Greiner S, Myers R, PengKW,Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006;44(6):1465-1477. (Pubitemid 44953652)
8. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009;69(1):82-91.
9. Griffin D, Measles virus. In: Griffin D, Lamb R, Martin M, Roizman B, Straus S, editors. Field's virology, Vol.1. Philadelphia: Lippincott Williams & Wilkins; 2001. p 1401.
10. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther 2001; 12(7):811-821. (Pubitemid 32692346)
11. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8(5):527-531. (Pubitemid 34546758)
12. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103(5):1641-1646. (Pubitemid 38268954)
13. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng KW, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82(6): 700-710. (Pubitemid 350114828)
14. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9:431-455.
15. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006; 34(6):713-720. (Pubitemid 43737093)
16. Tatsuo H, Yanagi Y. The morbillivirus receptor SLAM (CD150). Microbiol Immunol 2002;46(3):135-142.
17. Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T, Cattaneo R, Russell SJ. Antibody-targeted cell fusion. Nat Biotechnol 2004;22(3):331-336.
18. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23(2):209-214. (Pubitemid 40255331)
19. Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, Heston WD. Targeted treatment of prostate cancer. J Cell Biochem 2007; 102(3):571-579.
20. Gong MC, Chang SS, Sadelain M, Bander NH, Heston WD. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev 1999;18(4):483-490. (Pubitemid 30365326)
21. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25(5):540-547. (Pubitemid 350002961)
22. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J Urol 2003;170(6 Pt 2):S84-S88; discussion S88-S89. (Pubitemid 37413948)
23. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007;2(3):182-190. (Pubitemid 47554839)
24. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Riviere I, Larson SM, Koutcher JA, Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005;65(19):9080-9088. (Pubitemid 41377401)
25. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59(13):3192- 3198. (Pubitemid 29316022)
26. Metharom P, Liu C, Wang S, Stalboerger P, Chen G, Doyle B, Ikeda Y, Caplice NM. Myeloid lineage of high proliferative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo. Atherosclerosis 2008;198(1):29-38.
27. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, Canevari S, Hartmann LC, Peng KW. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6170-6178. (Pubitemid 44703783)
28. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1(2):123-127.
29. Hadac EM, Peng KW, Nakamura T, Russell SJ. Reengineering paramyxovirus tropism. Virology 2004;329(2):217-225.
30. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, SchroederM, Carlson B, Decker PA,WuW, James CD, Russell SJ, Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007;13(23):7155-7165. (Pubitemid 350276902)
31. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc 2008;83(12):1364-1372.
32. Kelly E, Russell SJ. History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 2007;15(4):651-659. (Pubitemid 46431984)
33. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007;28(7):326-333.
34. Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 2004;4(10):1685-1692. (Pubitemid 39371764)
35. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC.Aphase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12(22):6737-6747. (Pubitemid 44876843)
36. Munguia A, Ota T, Miest T, Russell SJ. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 2008;15(10):797-806. (Pubitemid 351627364)
37. Thorne SH, Contag CH. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 2008;15(10):753-758. (Pubitemid 351627358)
38. Power AT, Bell JC. Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 2008;15(10):772-779. (Pubitemid 351627361)
39. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.HumGene Ther 1999;10(8):1349-1358.
40. Carlisle RC, Benjamin R, Briggs SS, Sumner-Jones S, McIntosh J, Gill D, Hyde S, Nathwani A, Subr V, Ulbrich K, Seymour LW, Fisher KD. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med 2008; 10(4):400-411.
41. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad SciUSA2006;103(34):12873-12878.
42. Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM, Soeffker D, Federspiel MJ, Russell SJ. Pharmacokinetics of oncolytic measles virotherapy: Eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 2006;13(8):732-738. (Pubitemid 44100485)
43. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007;67(22):10939-10947. (Pubitemid 350145923)
44. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40(2-4):109-123. (Pubitemid 36959821)
45. Schneider-Schaulies J, Schneider-Schaulies S. Receptor interactions, tropism, and mechanisms involved in morbillivirus-induced immunomodulation. Adv Virus Res 2008;71:173-205.
46. Ohno S, Ono N, Seki F, Takeda M, Kura S, Tsuzuki T, Yanagi Y. Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. J Virol 2007;81(4):1650-1659. (Pubitemid 46214440)
47. HasegawaK,HuC, NakamuraT, Marks JD, Russell SJ, PengKW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 2007;81(23):13149-13157. (Pubitemid 350156953)
48. Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL, Verhoeyen E. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008; 112(13):4843-4852.
49. Funke S, Maisner A, Muhlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ. Targeted cell entry of lentiviral vectors. Mol Ther 2008;16(8):1427-1436.
50. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007; 50(4):472-483. (Pubitemid 46328190)
51. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995;55(7):1441-1443.
52. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma:A study of 184 cases. Cancer 1998;82(11):2256-2261. (Pubitemid 28240834)
53. Laidler P, Dulinska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005;435(1):1-14. (Pubitemid 40170010)
54. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-85. (Pubitemid 27079448)
55. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57(17):3629-3634. (Pubitemid 27381196)